Stellus Cap Investment (NYSE:SCM) Stock, Quote.Headers.trade-ideas

Stellus Cap Investment

Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through a first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. Business activity of the firm is functioned through the United States and it generates revenue in the form of interest income on debt investments and capital gains and distributions.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

BBLG

BLMZ

CERO

DAWN

ELAB

HOTH

INDV

IROQ

SLNA

TIVC

TWOU

VKTX

Why Indivior Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Short Ideas

Small Cap

As of Jan. 19, 2024, three stocks in the financial sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 3 Financial Stocks That May Implode In Q1

Penny Stocks

CVCY

NRDS

OVLY

SLQT

The most overbought stocks in the financial sector presents an opportunity to go short on these overvalued companies.

Top 5 Financial Stocks That May Fall Off A Cliff In Q1 2023

Stellus Capital Investment Corporation Common Stock

Stellus Capital Investment Corp

Schwab Strategic Trust Schwab Municipal Bond ETF

Scout Minerals Corp

SILVER CITY MINERALS LTD by SILVER CITY MINERALS LTD

Swisscom AG

Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $0.45 by 11.11 percent. This is a 1.96 percent decrease over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $26.626 million which missed the analyst consensus estimate of $27.006 million by 1.41 percent. This is a 0.15 percent increase over sales of $26.585 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Stellus Cap Investment Q2 2024 Adj. EPS $0.50 Beats $0.45 Estimate, Sales $26.626M Miss $27.006M Estimate

Shares of Indivior PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDV#NASDAQ">INDV</a>) rose sharply in today's pre-market trading after the company posted better-than-expected second-quarter results and announced an accelerated $100 million <a href="https://www.benzinga.com/quote/INDV/earnings">share repurchase program</a>.
Indivior reported quarterly earnings of 44 cents per share which beat the analyst consensus estimate of 14 cents per share. The company reported quarterly sales of $299.00 million which beat the analyst consensus estimate of $296.05 million.
Indivior shares jumped 14.5% to $12.46 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) rose 157.4% to $1.00 in pre-market trading after the company announced the export of nature-derived psilocybin to Australia and said a trial is projected to be initiated shortly following receipt of drug product by trial sites.</li>
<li>BloomZ Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) gained 81.2% to $4.44 in pre-market trading after dipping 43% on Wednesday. BloomZ recently priced its IPO at $4.30 per share.</li>
<li>Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares climbed 51.4% to $0.4576 in pre-market trading.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) gained 41.5% to $0.2988 in pre-market trading after gaining around 8% on Wednesday.</li>
<li>Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) shares gained 20.8% to $60.90 in pre-market trading after the company reported better-than-expected second-quarter EPS results.</li>
<li>Signing Day Sports, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGN#NYSE">SGN</a>) shares gained 15.9% to $0.2231 in pre-market trading after falling over 12% on Wednesday.</li>
<li>Stellus Capital Investment Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) shares surged 15.6% to $16.41 in pre-market trading.</li>
<li>ELEVAI Labs Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) gained 15.4% to $0.52 in pre-market trading.</li>
<li>Day One Biopharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAWN#NASDAQ">DAWN</a>) shares gained 7.9% to $16.60 in pre-market trading. Ipsen and Day One entered into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>2U, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWOU#NASDAQ">TWOU</a>) shares fell 67.7% to $1.33 in pre-market trading. 2U announced a strategic agreement with debtholders to eliminate half of debt and infuse $110 million in new capital.</li>
<li>IF Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IROQ#NASDAQ">IROQ</a>) shares declined 59.6% to $6.97 in pre-market trading.</li>
<li>Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) shares fell 22% to $67.85 in pre-market trading after the company reported worse-than-expected second-quarter sales results and issued third-quarter guidance below estimates. Also, the company acquired JenaValve and Endotronix.</li>
<li>Selina Hospitality PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNA#NASDAQ">SLNA</a>) shares fell 19.7% to $0.0367 in pre-market trading after jumping over 75% on Wednesday.</li>
<li>Ostin Technology Group Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) shares declined 18.7% to $0.36 in pre-market trading after gaining around 19% on Wednesday.</li>
<li>MaxLinear, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NYSE">MXL</a>) shares fell 18.1% to $18.25 in pre-market trading after the company reported worse-than-expected second-quarter financial results.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) fell 16.3% to $11.30 in pre-market trading after declining 10% on Wednesday.</li>
<li>Hoth Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) fell 15.9% to $0.8998 in pre-market trading. Hoth Therapeutics shares gained around 11% on Wednesday after the company signed an agreement with LTS Therapy Systems to develop and manufacture the HT-ALZ oral film prototype for Alzheimer&#8217;s disease.</li>
<li>Bone Biologics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares dipped 13% to $1.67 in pre-market trading after jumping 54% on Wednesday.</li>
<li>Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) shares fell 13% to $11.90 in pre-market trading following a second-quarter earnings miss.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39931967/nvidia-mcdonalds-and-2-other-stocks-insiders-are-selling">Nvidia, McDonald&#8217;s And 2 Other Stocks Insiders Are Selling</a></li>
</ul>

B. Riley Securities analyst Bryce Rowe upgrades Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) from Sell to Neutral and raises the price target from $12.5 to $13.25.

Upgrades

Price Target

Analyst Ratings

B. Riley Securities Upgrades Stellus Cap Investment to Neutral, Raises Price Target to $13.25

Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) reported quarterly earnings of $0.44 per share which missed the analyst consensus estimate of $0.45 by 2.22 percent. This is a 2.22 percent decrease over earnings of $0.45 per share from the same period last year. The company reported quarterly sales of $25.996 million which missed the analyst consensus estimate of $26.643 million by 2.43 percent. This is a 7.98 percent increase over sales of $24.075 million the same period last year.

Stellus Cap Investment Q1 2024 Adj EPS $0.44 Misses $0.45 Estimate, Sales $25.996M Miss $26.643M Estimate

Oppenheimer analyst Mitchel Penn maintains Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) with a Perform and maintains $14 price target.

Oppenheimer Maintains Perform on Stellus Cap Investment, Maintains $14 Price Target

B. Riley Securities analyst Bryce Rowe reiterates Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) with a Sell and lowers the price target from $13 to $12.5.

Reiteration

B. Riley Securities Reiterates Sell on Stellus Cap Investment, Lowers Price Target to $12.5

Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) reported quarterly earnings of $0.500 per share which beat the analyst consensus estimate of $0.450 by 11.11 percent. The company reported quarterly sales of $28.023 million which beat the analyst consensus estimate of $27.408 million by 2.24 percent. This is a 19.93 percent increase over sales of $23.367 million the same period last year.

Stellus Cap Investment Q4 2023 Adj EPS $0.500 Beats $0.450 Estimate, Sales $28.023M Beat $27.408M Estimate

Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) is set to give its latest quarterly earnings report on Monday, 2024-03-04. Here's what investors need to know before the announcement.
Analysts estimate that Stellus Cap Investment will report an earnings per share (EPS) of $0.45. 
Stellus Cap Investment bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.02, which was followed by a 4.75% drop in the share price the next day.
Here's a look at Stellus Cap Investment's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.47</td>
<td>0.47</td>
<td>0.44</td>
<td>0.38</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.49</td>
<td>0.51</td>
<td>0.45</td>
<td>0.44</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>-4.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1709308823_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Stellus Cap Investment were trading at $12.77 as of February 29. Over the last 52-week period, shares are down 16.93%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/SCM/earnings">To track all earnings releases for Stellus Cap Investment visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Stellus Cap Investment's Earnings: A Preview

B. Riley Securities analyst Bryce Rowe downgrades Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) from Neutral to Sell and announces $13 price target.

Downgrades

B. Riley Securities Downgrades Stellus Cap Investment to Sell, Announces $13 Price Target

Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) is set to give its latest quarterly earnings report on Tuesday, 2023-11-07. Here's what investors need to know before the announcement.
Analysts estimate that Stellus Cap Investment will report an earnings per share (EPS) of $0.47. 
Stellus Cap Investment bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.04, which was followed by a 4.17% drop in the share price the next day.
Here's a look at Stellus Cap Investment's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.47</td>
<td>0.44</td>
<td>0.38</td>
<td>0.30</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.51</td>
<td>0.45</td>
<td>0.44</td>
<td>0.35</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.17%</td>
<td>-1.54%</td>
<td>-0.7%</td>
<td>2.4%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2023/1699304510_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Stellus Cap Investment were trading at $13.29 as of November 03. Over the last 52-week period, shares are down 5.61%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/SCM/earnings">To track all earnings releases for Stellus Cap Investment visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Stellus Cap Investment

<h3>Upgrades</h3>
According to Barrington Research, the prior rating for Anika Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) was changed from Market Perform to Outperform. For the second quarter, Anika Therapeutics had an EPS of $0.06, compared to year-ago quarter EPS of $0.12. At the moment, the stock has a 52-week-high of $32.46 and a 52-week-low of $18.21. Anika Therapeutics closed at $18.38 at the end of the last trading period. 
According to B of A Securities, the prior rating for Parsons Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSN#NYSE">PSN</a>) was changed from Underperform to Buy. Parsons Corp earned $0.63 in the second quarter, compared to $0.41 in the year-ago quarter. At the moment, the stock has a 52-week-high of $55.28 and a 52-week-low of $38.68. Parsons Corp closed at $54.72 at the end of the last trading period. 
Janney Montgomery Scott upgraded the previous rating for Consolidated Water Co Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWCO#NASDAQ">CWCO</a>) from Neutral to Buy. Consolidated Water Co earned $0.46 in the second quarter, compared to $0.18 in the year-ago quarter. The stock has a 52-week-high of $25.00 and a 52-week-low of $13.39. At the end of the last trading period, Consolidated Water Co closed at $22.63. 
According to Piper Sandler, the prior rating for Coterra Energy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) was changed from Neutral to Overweight. For the second quarter, Coterra Energy had an EPS of $0.39, compared to year-ago quarter EPS of $1.35. At the moment, the stock has a 52-week-high of $32.46 and a 52-week-low of $22.25. Coterra Energy closed at $28.05 at the end of the last trading period. 
Goldman Sachs upgraded the previous rating for Teledyne Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDY#NYSE">TDY</a>) from Neutral to Buy. Teledyne Technologies earned $4.67 in the second quarter, compared to $4.43 in the year-ago quarter. The current stock performance of Teledyne Technologies shows a 52-week-high of $448.71 and a 52-week-low of $325.68. Moreover, at the end of the last trading period, the closing price was at $383.39. 
According to Goldman Sachs, the prior rating for Okta Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) was changed from Sell to Buy. For the first quarter, Okta had an EPS of $0.22, compared to year-ago quarter EPS of $0.27. At the moment, the stock has a 52-week-high of $109.34 and a 52-week-low of $44.13. Okta closed at $71.40 at the end of the last trading period. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings upgrades.</a>
<h3>Downgrades</h3>
According to DA Davidson, the prior rating for Xos Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOS#NASDAQ">XOS</a>) was changed from Buy to Neutral. Xos earned $0.14 in the second quarter, compared to $0.06 in the year-ago quarter. The current stock performance of Xos shows a 52-week-high of $2.14 and a 52-week-low of $0.21. Moreover, at the end of the last trading period, the closing price was at $0.37. 
According to Jefferies, the prior rating for NeoGames SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGMS#NASDAQ">NGMS</a>) was changed from Buy to Hold. In the second quarter, NeoGames showed an EPS of $0.00, compared to $0.49 from the year-ago quarter. The stock has a 52-week-high of $27.77 and a 52-week-low of $10.85. At the end of the last trading period, NeoGames closed at $27.11. 
According to Argus Research, the prior rating for Boston Properties Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXP#NYSE">BXP</a>) was changed from Buy to Hold. Boston Props earned $1.86 in the second quarter, compared to $1.94 in the year-ago quarter. The current stock performance of Boston Props shows a 52-week-high of $90.54 and a 52-week-low of $46.18. Moreover, at the end of the last trading period, the closing price was at $68.12. 
According to Seibert Williams, the prior rating for Range Resources Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) was changed from Buy to Hold. In the second quarter, Range Resources showed an EPS of $0.30, compared to $1.27 from the year-ago quarter. At the moment, the stock has a 52-week-high of $36.37 and a 52-week-low of $22.61. Range Resources closed at $32.45 at the end of the last trading period. 
According to Wedbush, the prior rating for Atreca Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCEL#NASDAQ">BCEL</a>) was changed from Outperform to Neutral. For the second quarter, Atreca had an EPS of $0.49, compared to year-ago quarter EPS of $0.72. At the moment, the stock has a 52-week-high of $2.78 and a 52-week-low of $0.50. Atreca closed at $0.56 at the end of the last trading period. 
According to Citigroup, the prior rating for Urban Outfitters Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) was changed from Buy to Neutral. For the first quarter, Urban Outfitters had an EPS of $0.56, compared to year-ago quarter EPS of $0.33. The stock has a 52-week-high of $37.81 and a 52-week-low of $18.76. At the end of the last trading period, Urban Outfitters closed at $36.41. 
Oppenheimer downgraded the previous rating for Stellus Capital Investment Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) from Outperform to Perform. In the second quarter, Stellus Cap Investment showed an EPS of $0.51, compared to $0.29 from the year-ago quarter. The current stock performance of Stellus Cap Investment shows a 52-week-high of $16.08 and a 52-week-low of $11.77. Moreover, at the end of the last trading period, the closing price was at $14.83. 
B of A Securities downgraded the previous rating for W.P. Carey Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPC#NYSE">WPC</a>) from Neutral to Underperform. In the second quarter, W.P. Carey showed an EPS of $1.36, compared to $1.31 from the year-ago quarter. At the moment, the stock has a 52-week-high of $89.39 and a 52-week-low of $65.78. W.P. Carey closed at $66.86 at the end of the last trading period. 
According to B of A Securities, the prior rating for EPR Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPR#NYSE">EPR</a>) was changed from Buy to Neutral. In the second quarter, EPR Props showed an EPS of $1.28, compared to $1.17 from the year-ago quarter. The current stock performance of EPR Props shows a 52-week-high of $55.90 and a 52-week-low of $33.92. Moreover, at the end of the last trading period, the closing price was at $42.82. 
According to B of A Securities, the prior rating for Keysight Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) was changed from Neutral to Underperform. Keysight Techs earned $2.12 in the second quarter, compared to $1.83 in the year-ago quarter. The current stock performance of Keysight Techs shows a 52-week-high of $189.38 and a 52-week-low of $139.62. Moreover, at the end of the last trading period, the closing price was at $156.54. 
For OpGen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPGN#NASDAQ">OPGN</a>), HC Wainwright &amp; Co. downgraded the previous rating of Buy to Neutral. In the second quarter, OpGen showed an EPS of $0.93, compared to $2.60 from the year-ago quarter. The stock has a 52-week-high of $12.62 and a 52-week-low of $0.24. At the end of the last trading period, OpGen closed at $0.26. 
BMO Capital downgraded the previous rating for Capri Holdings Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>) from Outperform to Market Perform. In the first quarter, Capri Holdings showed an EPS of $0.74, compared to $1.50 from the year-ago quarter. The stock has a 52-week-high of $69.25 and a 52-week-low of $34.17. At the end of the last trading period, Capri Holdings closed at $53.14. 
Piper Sandler downgraded the previous rating for Northern Oil &amp; Gas Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOG#NYSE">NOG</a>) from Overweight to Neutral. For the second quarter, Northern Oil &amp; Gas had an EPS of $1.49, compared to year-ago quarter EPS of $1.72. The current stock performance of Northern Oil &amp; Gas shows a 52-week-high of $42.86 and a 52-week-low of $24.22. Moreover, at the end of the last trading period, the closing price was at $42.02. 
Piper Sandler downgraded the previous rating for Berry Corp (bry) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRY#NASDAQ">BRY</a>) from Overweight to Neutral. For the second quarter, Berry Corp had an EPS of $0.15, compared to year-ago quarter EPS of $0.65. The current stock performance of Berry Corp shows a 52-week-high of $10.74 and a 52-week-low of $6.23. Moreover, at the end of the last trading period, the closing price was at $8.39. 
For Public Service Enterprise Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEG#NYSE">PEG</a>), UBS downgraded the previous rating of Buy to Neutral. Public Service Enterprise earned $0.70 in the second quarter, compared to $0.64 in the year-ago quarter. The stock has a 52-week-high of $69.90 and a 52-week-low of $52.53. At the end of the last trading period, Public Service Enterprise closed at $60.87. 
For Braemar Hotels &amp; Resorts Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHR#NYSE">BHR</a>), B. Riley Securities downgraded the previous rating of Buy to Neutral. In the second quarter, Braemar Hotels &amp; Resorts showed an EPS of $0.20, compared to $0.37 from the year-ago quarter. The current stock performance of Braemar Hotels &amp; Resorts shows a 52-week-high of $5.85 and a 52-week-low of $2.77. Moreover, at the end of the last trading period, the closing price was at $2.91. 
Bernstein downgraded the previous rating for Marriott International Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) from Outperform to Market Perform. In the second quarter, Marriott Intl showed an EPS of $2.26, compared to $1.80 from the year-ago quarter. At the moment, the stock has a 52-week-high of $210.98 and a 52-week-low of $135.90. Marriott Intl closed at $208.51 at the end of the last trading period. 
According to Barclays, the prior rating for CF Industries Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CF#NYSE">CF</a>) was changed from Overweight to Equal-Weight. For the second quarter, CF Industries Holdings had an EPS of $2.70, compared to year-ago quarter EPS of $6.19. The stock has a 52-week-high of $119.54 and a 52-week-low of $60.08. At the end of the last trading period, CF Industries Holdings closed at $79.49. 
Barclays downgraded the previous rating for The Mosaic Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>) from Equal-Weight to Underweight. Mosaic earned $1.04 in the second quarter, compared to $3.64 in the year-ago quarter. The stock has a 52-week-high of $63.16 and a 52-week-low of $31.44. At the end of the last trading period, Mosaic closed at $41.69. 
According to Barclays, the prior rating for Nutrien Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTR#NYSE">NTR</a>) was changed from Overweight to Underweight. In the second quarter, Nutrien showed an EPS of $2.53, compared to $5.85 from the year-ago quarter. The current stock performance of Nutrien shows a 52-week-high of $102.70 and a 52-week-low of $52.23. Moreover, at the end of the last trading period, the closing price was at $66.49. 
Jefferies downgraded the previous rating for Chindata Group Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CD#NASDAQ">CD</a>) from Buy to Hold. Chindata Group Holdings earned $0.12 in the first quarter, compared to $0.07 in the year-ago quarter. The current stock performance of Chindata Group Holdings shows a 52-week-high of $9.21 and a 52-week-low of $4.86. Moreover, at the end of the last trading period, the closing price was at $8.11. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings downgrades.</a>
<h3>Initiations</h3>
Northland Capital Markets initiated coverage on Manitex International Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTX#NASDAQ">MNTX</a>) with an Outperform rating. The price target for Manitex International is set to $10.00. For the second quarter, Manitex International had an EPS of $0.08, compared to year-ago quarter EPS of $0.05. The stock has a 52-week-high of $6.26 and a 52-week-low of $3.48. At the end of the last trading period, Manitex International closed at $5.05. 
For PLAYSTUDIOS Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYPS#NASDAQ">MYPS</a>), BTIG initiated coverage, by setting the current rating at Neutral. For the second quarter, PLAYSTUDIOS had an EPS of $0.01, compared to year-ago quarter EPS of $0.04. At the moment, the stock has a 52-week-high of $5.00 and a 52-week-low of $3.25. PLAYSTUDIOS closed at $3.82 at the end of the last trading period. 
Truist Securities initiated coverage on ODDITY Tech Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) with a Hold rating. The price target for ODDITY Tech is set to $54.00. For the second quarter, ODDITY Tech had an EPS of $0.56, compared to year-ago quarter EPS of $0.33. At the moment, the stock has a 52-week-high of $56.00 and a 52-week-low of $46.28. ODDITY Tech closed at $52.38 at the end of the last trading period. 
TD Cowen initiated coverage on Sana Biotechnology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) with a Market Perform rating. In the second quarter, Sana Biotechnology showed an EPS of $0.45, compared to $0.47 from the year-ago quarter. The stock has a 52-week-high of $8.75 and a 52-week-low of $2.99. At the end of the last trading period, Sana Biotechnology closed at $5.46. 
With a Neutral rating, B of A Securities initiated coverage on ODDITY Tech Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>). The price target seems to have been set at $60.00 for ODDITY Tech. In the second quarter, ODDITY Tech showed an EPS of $0.56, compared to $0.33 from the year-ago quarter. At the moment, the stock has a 52-week-high of $56.00 and a 52-week-low of $46.28. ODDITY Tech closed at $52.38 at the end of the last trading period. 
Morgan Stanley initiated coverage on ODDITY Tech Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) with a Equal-Weight rating. The price target for ODDITY Tech is set to $57.00. ODDITY Tech earned $0.56 in the second quarter, compared to $0.33 in the year-ago quarter. The current stock performance of ODDITY Tech shows a 52-week-high of $56.00 and a 52-week-low of $46.28. Moreover, at the end of the last trading period, the closing price was at $52.38. 
With a Buy rating, UBS initiated coverage on CymaBay Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBAY#NASDAQ">CBAY</a>). The price target seems to have been set at $18.00 for CymaBay Therapeutics. For the second quarter, CymaBay Therapeutics had an EPS of $0.01, compared to year-ago quarter EPS of $0.31. At the moment, the stock has a 52-week-high of $14.19 and a 52-week-low of $3.15. CymaBay Therapeutics closed at $13.47 at the end of the last trading period. 
With a Buy rating, HSBC initiated coverage on Monster Beverage Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>). The price target seems to have been set at $72.00 for Monster Beverage. Monster Beverage earned $0.39 in the second quarter, compared to $0.26 in the year-ago quarter. The current stock performance of Monster Beverage shows a 52-week-high of $60.47 and a 52-week-low of $42.80. Moreover, at the end of the last trading period, the closing price was at $58.18. 
Needham initiated coverage on Agilysys Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>) with a Buy rating. The price target for Agilysys is set to $92.00. Agilysys earned $0.18 in the first quarter, compared to $0.21 in the year-ago quarter. The current stock performance of Agilysys shows a 52-week-high of $88.16 and a 52-week-low of $46.01. Moreover, at the end of the last trading period, the closing price was at $70.08. 
Telsey Advisory Group initiated coverage on Academy Sports and Outdoors Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) with an Outperform rating. The price target for Academy Sports is set to $72.00. For the first quarter, Academy Sports had an EPS of $1.30, compared to year-ago quarter EPS of $1.72. The stock has a 52-week-high of $69.02 and a 52-week-low of $40.70. At the end of the last trading period, Academy Sports closed at $55.19. 
Goldman Sachs initiated coverage on Ducommun Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DCO#NYSE">DCO</a>) with a Neutral rating. The price target for Ducommun is set to $52.00. In the second quarter, Ducommun showed an EPS of $0.54, compared to $0.76 from the year-ago quarter. At the moment, the stock has a 52-week-high of $58.28 and a 52-week-low of $39.46. Ducommun closed at $45.76 at the end of the last trading period. 
JMP Securities initiated coverage on ODDITY Tech Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) with a Market Outperform rating. The price target for ODDITY Tech is set to $66.00. In the second quarter, ODDITY Tech showed an EPS of $0.56, compared to $0.33 from the year-ago quarter. The current stock performance of ODDITY Tech shows a 52-week-high of $56.00 and a 52-week-low of $46.28. Moreover, at the end of the last trading period, the closing price was at $52.38. 
With a Neutral rating, Goldman Sachs initiated coverage on ODDITY Tech Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>). The price target seems to have been set at $59.00 for ODDITY Tech. For the second quarter, ODDITY Tech had an EPS of $0.56, compared to year-ago quarter EPS of $0.33. The current stock performance of ODDITY Tech shows a 52-week-high of $56.00 and a 52-week-low of $46.28. Moreover, at the end of the last trading period, the closing price was at $52.38. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings initiations.</a>

Initiation

Intraday Update

AGYS

ANIK

BCEL

CBAY

CPRI

CTRA

CWCO

KEYS

MNST

MNTX

MYPS

NGMS

OKTA

OPGN

SANA

URBN

Benzinga's Top Ratings Upgrades, Downgrades For August 14, 2023

B. Riley Securities analyst Bryce Rowe maintains Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) with a Neutral and raises the price target from $14 to $14.25.

B. Riley Securities Maintains Neutral on Stellus Cap Investment, Raises Price Target to $14.25

Oppenheimer analyst Mitchel Penn downgrades Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) from Outperform to Perform and announces $15 price target.

Oppenheimer Downgrades Stellus Cap Investment to Perform, Announces $15 Price Target

Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.47 by 8.51 percent. This is a 75.86 percent increase over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $26.59 million which beat the analyst consensus estimate of $25.50 million by 4.25 percent. This is a 65.03 percent increase over sales of $16.11 million the same period last year.

Stellus Cap Investment Q2 Adj EPS $0.51 Beats $0.47 Estimate, Sales $26.59M Beat $25.50M Estimate

<h3>Upgrades</h3>
According to B of A Securities, the prior rating for West Pharmaceutical Services Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) was changed from Neutral to Buy. West Pharmaceutical Servs earned $1.98 in the first quarter, compared to $2.30 in the year-ago quarter. The current stock performance of West Pharmaceutical Servs shows a 52-week-high of $376.72 and a 52-week-low of $207.15. Moreover, at the end of the last trading period, the closing price was at $359.80. 
For Abcam PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABCM#NASDAQ">ABCM</a>), B of A Securities upgraded the previous rating of Neutral to Buy. NoneThe stock has a 52-week-high of $19.25 and a 52-week-low of $12.48. At the end of the last trading period, Abcam closed at $19.06. 
UBS upgraded the previous rating for AutoZone Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) from Neutral to Buy. In the third quarter, AutoZone showed an EPS of $34.12, compared to $29.03 from the year-ago quarter. The current stock performance of AutoZone shows a 52-week-high of $2750.00 and a 52-week-low of $1964.93. Moreover, at the end of the last trading period, the closing price was at $2497.37. 
JP Morgan upgraded the previous rating for MorphoSys AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOR#NASDAQ">MOR</a>) from Underweight to Overweight. MorphoSys earned $0.35 in the first quarter, compared to $4.03 in the year-ago quarter. At the moment, the stock has a 52-week-high of $7.66 and a 52-week-low of $3.19. MorphoSys closed at $7.07 at the end of the last trading period. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings upgrades.</a>
<h3>Downgrades</h3>
New Street Research downgraded the previous rating for Applied Materials Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) from Buy to Neutral. For the second quarter, Applied Mat had an EPS of $2.00, compared to year-ago quarter EPS of $1.85. At the moment, the stock has a 52-week-high of $142.53 and a 52-week-low of $71.18. Applied Mat closed at $140.11 at the end of the last trading period. 
For Truist Financial Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>), Odeon Capital downgraded the previous rating of Buy to Hold. In the first quarter, Truist Finl showed an EPS of $1.09, compared to $1.23 from the year-ago quarter. At the moment, the stock has a 52-week-high of $53.34 and a 52-week-low of $25.56. Truist Finl closed at $32.22 at the end of the last trading period. 
According to TD Cowen, the prior rating for Bausch Health Companies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>) was changed from Outperform to Market Perform. In the first quarter, Bausch Health Companies showed an EPS of $0.52, compared to $0.72 from the year-ago quarter. The current stock performance of Bausch Health Companies shows a 52-week-high of $10.23 and a 52-week-low of $4.00. Moreover, at the end of the last trading period, the closing price was at $7.44. 
For RPC Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RES#NYSE">RES</a>), Citigroup downgraded the previous rating of Neutral to Sell. In the first quarter, RPC showed an EPS of $0.39, compared to $0.07 from the year-ago quarter. NoneAt the moment, the stock has a 52-week-high of $11.40 and a 52-week-low of $5.71. RPC closed at $7.81 at the end of the last trading period. 
For NexTier Oilfield Solutions Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEX#NYSE">NEX</a>), Citigroup downgraded the previous rating of Buy to Neutral. In the first quarter, NexTier Oilfield showed an EPS of $0.66, compared to $0.08 from the year-ago quarter. The stock has a 52-week-high of $11.36 and a 52-week-low of $6.67. At the end of the last trading period, NexTier Oilfield closed at $9.52. 
According to B of A Securities, the prior rating for Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) was changed from Buy to Neutral. In the fourth quarter, Evotec showed an EPS of $0.08, compared to $0.23 from the year-ago quarter. At the moment, the stock has a 52-week-high of $15.04 and a 52-week-low of $7.80. Evotec closed at $11.85 at the end of the last trading period. 
B of A Securities downgraded the previous rating for SoFi Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) from Buy to Neutral. In the first quarter, SoFi Techs showed an EPS of $0.05, compared to $0.14 from the year-ago quarter. At the moment, the stock has a 52-week-high of $10.23 and a 52-week-low of $4.25. SoFi Techs closed at $9.55 at the end of the last trading period. 
Piper Sandler downgraded the previous rating for SoFi Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) from Overweight to Neutral. For the first quarter, SoFi Techs had an EPS of $0.05, compared to year-ago quarter EPS of $0.14. The stock has a 52-week-high of $10.23 and a 52-week-low of $4.25. At the end of the last trading period, SoFi Techs closed at $9.55. 
According to JP Morgan, the prior rating for Mersana Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRSN#NASDAQ">MRSN</a>) was changed from Overweight to Neutral. For the first quarter, Mersana Therapeutics had an EPS of $0.52, compared to year-ago quarter EPS of $0.59. The stock has a 52-week-high of $9.62 and a 52-week-low of $2.94. At the end of the last trading period, Mersana Therapeutics closed at $3.89. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings downgrades.</a>
<h3>Initiations</h3>
With a Neutral rating, DA Davidson initiated coverage on Elastic NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>). The price target seems to have been set at $60.00 for Elastic. In the fourth quarter, Elastic showed an EPS of $0.22, compared to $0.16 from the year-ago quarter. The current stock performance of Elastic shows a 52-week-high of $91.19 and a 52-week-low of $46.18. Moreover, at the end of the last trading period, the closing price was at $69.46. 
With a Buy rating, Maxim Group initiated coverage on Bionomics Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>). The price target seems to have been set at $7.00 for Bionomics. 
With a Neutral rating, Ladenburg Thalmann initiated coverage on Alliant Energy Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNT#NASDAQ">LNT</a>). The price target seems to have been set at $52.50 for Alliant Energy. In the first quarter, Alliant Energy showed an EPS of $0.65, compared to $0.77 from the year-ago quarter. NoneThe stock has a 52-week-high of $64.59 and a 52-week-low of $47.23. At the end of the last trading period, Alliant Energy closed at $53.75. 
With a Hold rating, Truist Securities initiated coverage on Hagerty Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGTY#NYSE">HGTY</a>). The price target seems to have been set at $11.00 for Hagerty. In the first quarter, Hagerty showed an EPS of $0.04, compared to $0.01 from the year-ago quarter. The current stock performance of Hagerty shows a 52-week-high of $13.58 and a 52-week-low of $7.82. Moreover, at the end of the last trading period, the closing price was at $9.17. 
Wells Fargo initiated coverage on MorphoSys AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOR#NASDAQ">MOR</a>) with an Overweight rating. The price target for MorphoSys is set to $17.00. In the first quarter, MorphoSys showed an EPS of $0.35, compared to $4.03 from the year-ago quarter. The current stock performance of MorphoSys shows a 52-week-high of $7.66 and a 52-week-low of $3.19. Moreover, at the end of the last trading period, the closing price was at $7.07. 
Wells Fargo initiated coverage on Bio-Rad Laboratories Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) with an Overweight rating. The price target for Bio-Rad Laboratories is set to $550.00. In the first quarter, Bio-Rad Laboratories showed an EPS of $3.34, compared to $4.94 from the year-ago quarter. The current stock performance of Bio-Rad Laboratories shows a 52-week-high of $570.22 and a 52-week-low of $345.53. Moreover, at the end of the last trading period, the closing price was at $379.06. 
Wells Fargo initiated coverage on Neogen Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) with an Overweight rating. The price target for Neogen is set to $22.00. For the third quarter, Neogen had an EPS of $0.12, compared to year-ago quarter EPS of $0.15. At the moment, the stock has a 52-week-high of $25.00 and a 52-week-low of $10.49. Neogen closed at $19.81 at the end of the last trading period. 
With a Buy rating, B. Riley Securities initiated coverage on Ares Capital Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCC#NASDAQ">ARCC</a>). The price target seems to have been set at $20.50 for Ares Capital. Ares Capital earned $0.57 in the first quarter, compared to $0.42 in the year-ago quarter. At the moment, the stock has a 52-week-high of $20.75 and a 52-week-low of $16.54. Ares Capital closed at $18.65 at the end of the last trading period. 
Roth MKM initiated coverage on GigaCloud Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCT#NASDAQ">GCT</a>) with a Buy rating. The price target for GigaCloud Tech is set to $13.00. For the first quarter, GigaCloud Tech had an EPS of $0.39, compared to year-ago quarter EPS of $0.13. The current stock performance of GigaCloud Tech shows a 52-week-high of $61.98 and a 52-week-low of $4.14. Moreover, at the end of the last trading period, the closing price was at $7.84. 
With a Buy rating, Jefferies initiated coverage on LendingClub Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>). The price target seems to have been set at $13.50 for LendingClub. LendingClub earned $0.13 in the first quarter, compared to $0.39 in the year-ago quarter. The stock has a 52-week-high of $15.78 and a 52-week-low of $6.30. At the end of the last trading period, LendingClub closed at $9.64. 
With a Neutral rating, UBS initiated coverage on Guess? Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>). The price target seems to have been set at $22.00 for Guess. In the first quarter, Guess showed an EPS of $0.07, compared to $0.24 from the year-ago quarter. The current stock performance of Guess shows a 52-week-high of $24.14 and a 52-week-low of $14.27. Moreover, at the end of the last trading period, the closing price was at $20.85. 
UBS initiated coverage on Oxford Industries Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) with a Neutral rating. The price target for Oxford Industries is set to $110.00. In the first quarter, Oxford Industries showed an EPS of $3.78, compared to $3.50 from the year-ago quarter. At the moment, the stock has a 52-week-high of $123.37 and a 52-week-low of $82.16. Oxford Industries closed at $102.57 at the end of the last trading period. 
With a Buy rating, Jefferies initiated coverage on Atlanticus Holdings Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATLC#NASDAQ">ATLC</a>). The price target seems to have been set at $50.00 for Atlanticus Holdings. In the first quarter, Atlanticus Holdings showed an EPS of $1.08, compared to $1.96 from the year-ago quarter. At the moment, the stock has a 52-week-high of $42.97 and a 52-week-low of $21.65. Atlanticus Holdings closed at $42.97 at the end of the last trading period. 
With a Neutral rating, B. Riley Securities initiated coverage on Stellus Capital Investment Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>). The price target seems to have been set at $14.00 for Stellus Cap Investment. In the first quarter, Stellus Cap Investment showed an EPS of $0.45, compared to $0.29 from the year-ago quarter. At the moment, the stock has a 52-week-high of $16.08 and a 52-week-low of $11.06. Stellus Cap Investment closed at $14.02 at the end of the last trading period. 
B. Riley Securities initiated coverage on Sixth Street Specialty Lending Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSLX#NYSE">TSLX</a>) with a Buy rating. The price target for Sixth Street Specialty is set to $21.00. For the first quarter, Sixth Street Specialty had an EPS of $0.55, compared to year-ago quarter EPS of $0.49. The stock has a 52-week-high of $19.83 and a 52-week-low of $16.03. At the end of the last trading period, Sixth Street Specialty closed at $18.55. 
BTIG initiated coverage on Olo Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLO#NYSE">OLO</a>) with a Neutral rating. Olo earned $0.03 in the first quarter, compared to $0.01 in the year-ago quarter. At the moment, the stock has a 52-week-high of $14.07 and a 52-week-low of $5.74. Olo closed at $7.37 at the end of the last trading period. 
With a Buy rating, BTIG initiated coverage on Shift4 Payments Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>). The price target seems to have been set at $83.00 for Shift4 Payments. In the first quarter, Shift4 Payments showed an EPS of $0.51, compared to $0.15 from the year-ago quarter. The stock has a 52-week-high of $76.40 and a 52-week-low of $29.41. At the end of the last trading period, Shift4 Payments closed at $63.79. 
BTIG initiated coverage on Toast Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) with a Neutral rating. For the first quarter, Toast had an EPS of $0.16, compared to year-ago quarter EPS of $0.20. The current stock performance of Toast shows a 52-week-high of $26.04 and a 52-week-low of $12.16. Moreover, at the end of the last trading period, the closing price was at $23.03. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings initiations.</a>

ABCM

AMAT

ARCC

ATLC

BNOX

ESTC

FOUR

HGTY

Morgan Stanley Capital Protected Notes for S&P 500 Index

MRSN

NEOG

SOFI

TOST

TSLX

Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2023

B. Riley Securities analyst Bryce Rowe initiates coverage on Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) with a Neutral rating and announces Price Target of $14.

B. Riley Securities Initiates Coverage On Stellus Cap Investment with Neutral Rating, Announces Price Target of $14

Keefe, Bruyette &amp; Woods analyst Ryan Lynch maintains Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) with a Market Perform and lowers the price target from $15.5 to $15.

Keefe, Bruyette & Woods Maintains Market Perform on Stellus Cap Investment, Lowers Price Target to $15

Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) reported its Q1 earnings results on Tuesday, May 9, 2023 at 06:15 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Stellus Cap Investment beat estimated earnings by 2.27%, reporting an EPS of $0.45 versus an estimate of $0.44.
Revenue was up $8.58 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.06 which was followed by a 0.7% drop in the share price the next day.
Here's a look at Stellus Cap Investment's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
<th>Q2 2022</th>
<th>Q1 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.38</td>
<td>0.30</td>
<td>0.29</td>
<td>0.30</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.44</td>
<td>0.35</td>
<td>0.29</td>
<td>0.29</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>21.45M</td>
<td>17.59M</td>
<td>16.45M</td>
<td>16.33M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>23.37M</td>
<td>20.14M</td>
<td>16.11M</td>
<td>15.49M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Stellus Cap Investment <a href="https://www.benzinga.com/quote/SCM/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Stellus Cap Investment: Q1 Earnings Insights

Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.44 by 2.27 percent. This is a 55.17 percent increase over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $24.07 million which beat the analyst consensus estimate of $23.61 million by 1.97 percent. This is a 55.38 percent increase over sales of $15.49 million the same period last year.

Stellus Cap Investment Q1 EPS $0.45 Beats $0.44 Estimate, Sales $24.07M Beat $23.61M Estimate

Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) is set to give its latest quarterly earnings report on Tuesday, 2023-05-09. Here's what investors need to know before the announcement.
Analysts estimate that Stellus Cap Investment will report an earnings per share (EPS) of $0.44. 
Stellus Cap Investment bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.06, which was followed by a 0.7% drop in the share price the next day.
Here's a look at Stellus Cap Investment's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
<th>Q2 2022</th>
<th>Q1 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.38</td>
<td>0.30</td>
<td>0.29</td>
<td>0.30</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.44</td>
<td>0.35</td>
<td>0.29</td>
<td>0.29</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.7%</td>
<td>1.86%</td>
<td>-1.78%</td>
<td>-5.9%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2023/1683568945_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Stellus Cap Investment were trading at $14.33 as of May 05. Over the last 52-week period, shares are up 13.22%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/SCM/earnings">To track all earnings releases for Stellus Cap Investment visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Preview: Stellus Cap Investment's Earnings

Stellus Capital Investment declares $0.1333 dividend

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into all of the biggest pre-market stock movers on Thursday morning!



Moving stocks this morning are earnings reports, a public debut, a bankruptcy filing and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Psyence Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/pbm-stock-quote/">PBM</a>) stock is rocketing more than 211% after announcing a <a href="https://www.globenewswire.com/news-release/2024/07/24/2918366/0/en/Psyence-Biomed-Announces-Export-of-Nature-Derived-Psilocybin-to-Australia-and-Provides-Update-on-Upcoming-Phase-IIb-Trial.html">psilocybin export to Australia</a> and providing a clinical trial update.</li>



<li>Tivic Health Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/tivc-stock-quote/">TIVC</a>) shares are soaring over 91% after <a href="https://www.nasdaq.com/press-release/tivic-health-expands-intellectual-property-portfolio-2024-07-23">expanding its intellectual property portfolio</a>.</li>



<li>BloomZ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) stock is surging more than 48% <a href="https://www.wboy.com/business/press-releases/accesswire/891946/bloomz-inc-announces-pricing-of-5-38-million-initial-public-offering/">following its recent public debut</a>.</li>



<li>Cero Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cero-stock-quote/">CERO</a>) shares are rising over 32% alongside heavy pre-market trading.</li>



<li>Viking Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/vktx-stock-quote/">VKTX</a>) stock is increasing more than 17% after <a href="https://www.prnewswire.com/news-releases/viking-therapeutics-reports-second-quarter-2024-financial-results-and-provides-corporate-update-302205767.html">releasing its Q2 earnings report</a>.</li>



<li>VS Media (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsme-stock-quote/">VSME</a>) shares are gaining close to 17% with strong early morning trading today.</li>



<li>Indivior (NASDAQ:<a href="https://investorplace.com/stock-quotes/indv-stock-quote/">INDV</a>) stock is heading over 14% higher on <a href="https://www.marketwatch.com/story/indivior-shares-jump-on-increased-revenue-100m-share-buyback-5cd4e573?mod=newsviewer_click">Q2 revenue growth</a> and a share buyback.</li>



<li>Signing Day Sports (NYSEMKT:<a href="https://investorplace.com/stock-quotes/sgn-stock-quote/">SGN</a>) shares are jumping more than 14% without any clear news this morning.</li>



<li>Davis Commodities (NASDAQ:<a href="https://investorplace.com/stock-quotes/dtck-stock-quote/">DTCK</a>) stock is getting a 14% boost on Thursday morning.</li>



<li>Stellus Capital Investment (NYSE:<a href="https://investorplace.com/stock-quotes/scm-stock-quote/">SCM</a>) shares are up over 12% despite a lack of news today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>2U (NASDAQ:<a href="https://investorplace.com/stock-quotes/twou-stock-quote/">TWOU</a>) stock is plummeting more than 68% with a <a href="https://www.nasdaq.com/press-release/2u-takes-strategic-action-significantly-strengthen-balance-sheet-and-position-company">Chapter 11 bankruptcy filing</a>.</li>



<li>Edwards Lifesciences (NYSE:<a href="https://investorplace.com/stock-quotes/ew-stock-quote/">EW</a>) shares are diving over 22% alongside <a href="https://www.nasdaq.com/press-release/edwards-lifesciences-reports-second-quarter-results-2024-07-24">lackluster Q2 results</a>.</li>



<li>Selina Hospitality (NASDAQ:<a href="https://investorplace.com/stock-quotes/slna-stock-quote/">SLNA</a>) stock is tumbling more than 19% following a rally yesterday.</li>



<li>MaxLinear (NASDAQ:<a href="https://investorplace.com/stock-quotes/mxl-stock-quote/">MXL</a>) shares are taking an over 18% beating after <a href="https://finance.yahoo.com/news/maxlinear-inc-announces-second-quarter-200500103.html">releasing its Q2 earnings report</a>.</li>



<li>Fangdd Network (NASDAQ:<a href="https://investorplace.com/stock-quotes/duo-stock-quote/">DUO</a>) stock is sliding more than 17% after a rally yesterday.</li>



<li>IF Bancorp (NASDAQ:<a href="https://investorplace.com/stock-quotes/iroq-stock-quote/">IROQ</a>) shares are falling over 16% despite a lack of news this morning.</li>



<li>Regencell Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgc-stock-quote/">RGC</a>) stock is dropping more than 16% <a href="https://investorplace.com/2024/07/what-is-going-on-with-regencell-bioscience-rgc-stock-today/">alongside recent volatility</a>.</li>



<li>Hoth Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/hoth-stock-quote/">HOTH</a>) shares are retreating over 15% <a href="https://investorplace.com/2024/07/why-is-hoth-therapeutics-hoth-stock-moving-today/">with recent volatility</a>.</li>



<li>Nuzee (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) stock is decreasing more than 14% <a href="https://investorplace.com/2024/07/why-is-nuzee-nuze-stock-up-133-today/">after rallying yesterday</a>.</li>



<li>Dermata Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) shares close out our pre-market stock movers down over 14% <a href="https://investorplace.com/2024/07/why-is-dermata-therapeutics-drma-stock-up-200-today/">following a Wednesday rally</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-july-25th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Any investor who is looking for a stable source of income would be wise to consider monthly <a href="https://investorplace.com/stock-types/dividend-stocks/">dividend stocks</a>.



 Unlike traditional dividend stocks that pay out quarterly or annually, monthly dividend stocks provide a consistent and predictable income stream 12 times a year. 



That makes them attractive for retirees, income-focused investors, and anyone who wants to reinvest their dividends for compounded growth.



Monthly dividend stocks are particularly attractive because of their steady cash flow. Dividend payments align with regular household expenses, making them useful for meeting ongoing costs.



It&rsquo;s much easier to manage your finances when you know you have roughly the same income coming in every month, rather than getting a dividend payment on a quarterly basis.



But you don&rsquo;t have to be a retiree to enjoy the benefits of monthly dividend stocks. These names are also ideal for people who want to accelerate the beauty of compounded growth. 



Because you&rsquo;re getting your payment 12 times a year instead of four times a year, you can invest your dividend faster and get your money working for you immediately.



I&rsquo;m using the Portfolio Grader and the Dividend Grader to choose the best monthly dividend stocks on the market. 



These tools evaluate stocks based on their dividend payout, as well as earnings performance, growth and analyst sentiment. Even stocks that have an overall lower grade in the Portfolio Grader can make a strong monthly dividend stock, as you&rsquo;ll see.



If you&rsquo;re an investor who is looking for both income and growth potential, then these monthly dividend stocks are for you.



<h2>Main Street Capital (MAIN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/06/main-street-capital-1600-300x169.jpg" alt="The logo for Main Street Capital Corp (MAIN) is displayed on a smartphone in front of a stock chart."><div>Source: Piotr Swat / Shutterstock</div></div>Main Street Capital (NYSE:<a href="https://investorplace.com/stock-quotes/main-stock-quote/">MAIN</a>) is a business development company, or BDC. These types of companies are like real estate investment trusts, in that they have a tax structure that requires the BDC to distribute at least 90% of their income to investors.



BDCs invest in private companies, with Main Street having a focus on lower and middle market firms. In the second quarter alone, Main Street originated new or increased commitments of $375.9 million. As of June 30, the private equity firm&rsquo;s loan portfolio included total investments of $1.8 billion across 92 unique borrowers.



Main Street won&rsquo;t issue its second-quarter financial report until Aug. 8, but <a href="https://www.mainstcapital.com/investors/news-events/press-releases/detail/2689/main-street-announces-preliminary-estimate-of-second">preliminary results look solid</a>. The company said its net investment income will be $1 to $1.02 per share, while distributable net investment income will be $1.06 to $1.08 per share. Main Street increased its dividend payments in the quarter by 13% from a year ago.



Main Street pays a dividend yield of 8% and gets a &ldquo;B&rdquo; rating in the Dividend Grader and an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>PennantPark Floating Rate Capital (PFLT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/dividend-stocks-to-buy-300x169.jpg" alt='dividend stocks: A calculator projecting the word "DIVIDEND" rests on a pile of gold and silver coins.'><div>Source: Shutterstock</div></div>Another BDC on the list is PennantPark Floating Rate Capital (NYSE:<a href="https://investorplace.com/stock-quotes/pflt-stock-quote/">PFLT</a>), which invests in middle-market companies with first-lien debt. 



It&rsquo;s always important to know what a BDC is investing in because, unfortunately, sometimes companies fail and can&rsquo;t repay their loans. But first-lien debt is a pretty safe investment because those types of debts are guaranteed with collateral.



PennantPark also has some floating rate senior secured loans on its books, second lien secured debt and subordinated debt. The Miami-based BDC is currently managing approximately&nbsp;$7.7 billion&nbsp;of investable capital.



Earnings for the second quarter of fiscal 2024, (<a href="https://pflt.pennantpark.com/news-releases/news-release-details/pennantpark-floating-rate-capital-ltd-announces-financial-46">ending March 31</a>), included $19.1 million in investment income and 31 cents per share in dividend payments, compared to a year ago when it had $13.7 million in investment income and paid out 28.5 cents per share in dividends.



PFLT provides a strong monthly dividend payout of 10.9%. It gets a &ldquo;C&rdquo; rating in the Portfolio Grader, but a &ldquo;B&rdquo; rating in the Dividend Grader.



<h2>Permian Basin Royalty Trust (PBT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/04/dividend-stocks-bag-plants-1600-300x169.jpg" alt="Graphic of man relaxing in chair with giant dividend bag behind him and money plants in pots in front of him"><div>Source: shutterstock.com/Katakari</div></div>If you&rsquo;ve even dabbled in oil or gas stocks, you&rsquo;re likely familiar with the Permian Basin &ndash; a massive oil reserve that spans from western Texas to southeast New Mexico.



For 100 years, oil drillers have been working the Permian Basin and so far have removed 30 billion barrels of oil. But there&rsquo;s still plenty left, with experts calculating that the reserve still has another 20 billion barrels left to withdraw.



That brings us to the Permian Basin Royalty Trust (NYSE:<a href="https://investorplace.com/stock-quotes/pbt-stock-quote/">PBT</a>). Royalty trusts own the rights to assets such as mineral rights or oil reserves. Companies that want to drill or mine the land pay royalties to the landowner, who then distributes the payments to investors.



Because the distributions aren&rsquo;t considered to be taxable events, the monthly dividend yields are high, which makes royalty trusts a good pick for a monthly dividend stock. 



The trust&rsquo;s principal assets are a 75% net overriding royalty interest carved out by Southland Royalty Company from its fee mineral interest in the Waddell Ranch properties in Crane County, Texas, as well as a 95% net overriding royalty interest from Southland&rsquo;s major producing royalty properties in Texas.



Royalty income in the first quarter was $6 million, versus $5.2 million in the same period a year ago. Distributable income per unit was 12 cents per unit, an increase from 10 cents per unit in the first quarter of 2023.



PBT stock offers a dividend yield of 6%. That gives it a &ldquo;D&rdquo; rating in the Portfolio Grader, but an &ldquo;A&rdquo; rating in the Dividend Grader.



<h2>Apple Hospitality REIT (APLE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/04/dividend-stocks1600-300x169.png" alt="Two hand giving heap of coins money with up arrow and percentage symbol for financial banking increase interest rate or mortgage investment dividend from business growth concept. Dividend stocks"><div>Source: Dilok Klaisataporn / Shutterstock.com</div></div>Real estate investment trusts are always going to be an ideal choice for a dividend stock. REITs invest in various forms of real estate, and often are focused on a specific type of real estate, such as health care, residential or commercial property.



The Apple Hospitality REIT (NYSE:<a href="https://investorplace.com/stock-quotes/aple-stock-quote/">APLE</a>) is a Virginia-based company that invests in upscale hotel properties in the U.S. IT has a portfolio 224 hotels and 30,000 guest rooms throughout 37 states and the District of Columbia. 



The company&rsquo;s investments include 100 hotels branded by&nbsp;Marriott&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/mar-stock-quote/">MAR</a>), 120&nbsp;Hilton&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/hlt-stock-quote/">HLT</a>) hotels and five hotels branded by Hyatt (NYSE:<a href="https://investorplace.com/stock-quotes/h-stock-quote/">H</a>). Its <a href="https://ir.applehospitalityreit.com/News/news-details/2024/Apple-Hospitality-REIT-Acquires-the-Embassy-Suites-by-Hilton-Madison-Downtown/default.aspx">most recent investment</a> is an Embassy Suites by Hilton property in Madison, Wisconsin, that it purchased in June for $79.5 million.



<a href="https://ir.applehospitalityreit.com/News/news-details/2024/Apple-Hospitality-REIT-Reports-Results-of-Operations-for-First-Quarter-2024/default.aspx">Earnings in the first quarter</a> included net income of $54 million, up 64.2% from a year ago. Income per share came in at 22 cents, up from 14 cents in the first quarter of 2023.



APLE pays a monthly dividend yield of 6.3%, giving it a &ldquo;C&rdquo; rating in the Portfolio Grader and a &ldquo;B&rdquo; rating in the Dividend Grader.



<h2>Cross Timbers Royalty Trust (CRT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/dividends-letters-300x169.jpg" alt="dividend stocks"><div>Source: Shutterstock</div></div>Cross Timbers Royalty Trust (NYSE:<a href="https://investorplace.com/stock-quotes/crt-stock-quote/">CRT</a>) is a gas and oil royalty trust. It was formed in 1991 to convey royalties from&nbsp;XTO Energy&rsquo;s&nbsp;ownership of gas properties in the San Juan Basin of New Mexico and oil interests in Texas and Oklahoma.



Cross Timbers has a 90% profit interest in XTO&rsquo;s properties in Texas, Oklahoma and New Mexico, but most net profits income is from long-active gas properties in the San Juan Basin of northwestern New Mexico. There are no production or development costs, so the payout is primarily affected by sales volume and prices.



Cross Timbers also has a 75% profit interest in XTO&rsquo;s working interests in seven large, predominantly oil-producing properties in Texas and Oklahoma. However, those profits are impacted by production and development costs.



Income in the <a href="https://crt-crosstimbers.com/wp-content/uploads/2024/06/CRT-1Q_2024-Reportfor-Website.pdf">first quarter of 2024</a> was $1.85 million, but that was down from $3.92 million in the same quarter a year ago. Income per unit was 24.8 cents per unit, down from 60.6 cents in the same period a year ago. Cross Timbers says profits were affected by decreased gas production, lower gas and oil prices and increased development costs.



CRT currently pays a dividend yield of 11.3% and gets a &ldquo;D&rdquo; rating in the Portfolio Grader and a &ldquo;B&rdquo; rating in the Dividend Grader.



<h2>Gladstone Capital (GLAD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/07/gladstone-capital-1600-300x169.jpg" alt=""><div>Source: MacroEcon / Shutterstock.com</div></div>Gladstone Capital (NYSE:<a href="https://investorplace.com/stock-quotes/glad-stock-quote/">GLAD</a>) is a business development company that specializes in farmland. The Virginia-based company invests in loans to lower-middle market businesses, having made more than 260 deals since its inception in 2001.



The company currently invests in a variety of companies, including aerospace firms, telecommunications, health care, manufacturers, real estate, food services and automotive companies.



Earnings for the <a href="https://www.gladstonecapital.com/investors/news-events/press-releases/detail/358/gladstone-capital-corporation-reports-financial-results-for">second quarter of fiscal 2024</a> (ending March 31) included $23.99 million in investment income, up 3.3% from a year ago. Net investment income of $10.77 million was down 9.7% from a year ago, and cash distributions fell from 27 cents per share to 25 cents per share.



The company also executed a 1-for-2 reverse stock split in April.



GLAD stock has a dividend payout ratio of 8.3%, and gets &ldquo;B&rdquo; ratings in both the Portfolio Grader and the Dividend Grader.



<h2>Stellus Capital Investment Corp. (SCM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/04/dividend-stocks1600-1-300x169.png" alt="interest rates and dividends, investment returns, income, retirement Compensation fund, investment, dividend tax. pile of coins and upward direction percentage symbol. saving money for investment. Dividend stocks"><div>Source: Suri_Studio / Shutterstock.com</div></div>Stellus Capital Investment Corp. (NYSE:<a href="https://investorplace.com/stock-quotes/scm-stock-quote/">SCM</a>) is a private equity firm that focuses on private middle-market companies, which it describes as those with between $5 million and $50 million of earnings before taxes, depreciation and amortization.



The company currently has 94 active investments with $2.9 million in assets under management. Its portfolio of active investments includes firms that are in the aerospace, business services, and capital equipment fields.



Earnings in the first quarter were $10.24 million and 42 cents per share, up from $9.07 million and 46 cents per share a year ago.



Stellus offers a monthly dividend yield of 11.1%, giving it a &ldquo;C&rdquo; rating in the Portfolio Grader and a &ldquo;B&rdquo; rating in the Dividend Grader.



On the date of publication, neither Louis&nbsp;Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://url.us.m.mimecastprotect.com/s/AAadCPNlWWs3yKYns0yRM6?domain=investorplace.com/">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) and positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
The post <a href="https://investorplace.com/market360/2024/08/7-monthly-dividend-stocks-to-buy-in-august/">7 Monthly Dividend Stocks to Buy in August</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 Monthly Dividend Stocks to Buy in August

Stellus Capital Investment Core NII of $0.50 beats by $0.05

Stellus Capital Investment Corporation (SCM) Q2 2024 Earnings Call Transcript

Stellus Capital: Potential Negative Growth, Non-Accruals And Lofty Valuation Could Hinder Returns

In a report released yesterday, Paul Johnson from KBW maintained a Hold rating on Stellus Capital (SCM – Research Report), with a price target of $...

KBW Keeps Their Hold Rating on Stellus Capital (SCM)

Stellus Capital: 12% Yield, Monthly Payer, Reasonable Valuation

80 Monthly Paid Dividend Stocks And 80 MoPay Funds For August

Stellus Capital: Consistent Performance But Still Awaiting A Better Entry

AGNC

AMZY

APLE

BITO

BXMT

CNDCF

DISO

DRMA

DTCK

EARN

FNNCF

GBDC

GLAD

GOOY

ICRP

MAIN

MAXI

MSFO

NUZE

OARK

PEYUF

PFLT

PNNT

PYPY

TTBKF

TUERF

VSME

YBTC

YMAX

Press Releases

Stellus Capital Investment Corporation Reports Results for its Fourth Fiscal Quarter and Year Ended December 31, 2023

Dividends

Stellus Capital Investment Corporation Announces $0.40 Second Quarter 2024 Regular Dividend, Payable Monthly in Increments of $0.1333 in May, June, and July 2024

Stellus Capital Investment Corporation Announces Ex-Dividend Date Changes to its $0.40 Second Quarter 2024 Regular Dividend, Payable Monthly in Increments of $0.1333 in May, June, and July 2024

Stellus Capital Investment Corporation Schedules First Quarter 2024 Financial Results Conference Call

Stellus Capital Investment Corporation Reports Results for its First Fiscal Quarter Ended March 31, 2024

Stellus Capital Investment Corporation Announces $0.40 Third Quarter 2024 Regular Dividend, Payable Monthly in Increments of $0.1333 in August, September, and October 2024

Stellus Capital Investment Corporation Schedules Second Quarter 2024 Financial Results Conference Call

Stellus Capital Investment Corporation Reports Results for its Second Fiscal Quarter Ended June 30, 2024

AlTi Global

ArrowMark Financial Corp. - Closed End Fund

ArrowMark Financial

Bridge Investment Group Holdings Inc. Class A Common Stock

Bridge Investment Group

Diamond Hill Investment Group, Inc. - Class A Common Stock

Diamond Hill Investment

Ellington Credit Company Common Shares of Beneficial Interest

Ellington Credit

Gladstone Investment Corporation - Business Development Company

Gladstone Inv

GCM Grosvenor Inc. - Class A Common Stock

GCM Grosvenor

Gladstone Capital Corporation - Closed End Fund

Gladstone Cap

Highest Performances Holdings Inc. - American Depository Shares

Highest Performances

Horizon Technology Finance Corporation - Common Stock

Horizon Tech Finance

Monroe Capital Corporation - Closed End Fund

Monroe Cap

Noah Holdings Limited American Depositary Shares

Noah Holdings

OFS Credit Company, Inc. - Closed End Fund

OFS Credit Co

OFS Capital Corporation - Closed End Fund

OFS Capital

Oxford Square Capital Corp. - Closed End Fund

Oxford Square Cap

PennantPark Investment Corporation Common Stock

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Stellus Cap Investment

Stellus Cap Investment (SCM) Forecast

Stellus Cap Investment (NYSE:SCM) Stock, Quote.Headers.trade-ideas